# Efficacy and Safety of Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC: A Retrospective Real-world Study

> **NCT05638438** · — · UNKNOWN · sponsor: **Zhujiang Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Hepatocellular Carcinoma Non-resectable

## Interventions

- **PROCEDURE:** transarterial therapies

## Key facts

- **NCT ID:** NCT05638438
- **Lead sponsor:** Zhujiang Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-02
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05638438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05638438, "Efficacy and Safety of Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC: A Retrospective Real-world Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05638438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*